Results 271 to 280 of about 591,464 (366)

Rebound regrowth phenomenon in patients with pediatric low-grade gliomas treated with MAPK inhibitors - a systematic review. [PDF]

Oncol Rev
Styczewska M, Lyzinska W, Krawczyk MA, Bien E.   +3 more
europepmc   +1 more source

Early Antibiotic Discontinuation for Children With a Positive Rapid Respiratory Viral Test Hospitalized for Suspected Bacterial Tracheostomy-Associated Infections. [PDF]

Pediatr Pulmonol
Russell CJ, Kono N, Rush M, Hahn A, Forster CS, Cogen JD, DeYoung SH, Morrison JM, Thomson J, Mairal SV, Mack WJ, Neely MN, Simon TD, Pediatric Research in Inpatient Settings Network.   +13 more
europepmc   +1 more source

Research Ethics in Stopping Opioid Use Disorder Medication. [PDF]

JAMA Psychiatry
Weiss RD, Nunes EV, Provost SE.
europepmc   +1 more source

Clinically Relevant Bleeding in Individuals With Cancer: Insights From a Nationwide Cohort Study

American Journal of Hematology, EarlyView.
ABSTRACT Cancer care is often complicated by coagulopathy leading to thrombosis and bleeding. While venous thromboembolism (VTE) has been extensively studied, bleeding remains an underestimated threat. To address this knowledge gap, we leveraged the Epic Cosmos database to determine the impact of cancer‐associated clinically relevant bleeding (CRB) in ...
Ming Y. Lim, Radhika Gangaraju, Omid Jafari, Zihan Yang, Joyce W. T. Tiong, Elizabeth C. L. Chiang, Shengling Ma, Jun Y. Jiang, Justine Ryu, Barbara D. Lam, Mrinal Ranjan, Ang Li   +11 more
wiley   +1 more source

Perioperative antiplatelet management in CAD patients undergoing spinal fusion: balancing cardiovascular safety and bleeding risk. [PDF]

Am J Transl Res
Liu Z, Zhou J, Yan P, Chen D, Xu J.
europepmc   +1 more source

The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta‐Analysis of the European Myeloma Network (EMN)

American Journal of Hematology, EarlyView.
Our meta‐analysis showed significant improvement of PFS with lenalidomide, proteasome inhibitors, and CD38‐based therapies. A significant OS benefit was noted only with lenalidomide in transplant‐eligible (TE) patients, while CD38‐directed therapy showed a trend toward improved OS.
Heinz Ludwig, Evangelos Terpos, Francesca Gay, Niels W. C. J. van de Donk, Sarah Bernhard, Monika Engelhardt, Gordon Cook, Fredrik Schjesvold, Hermann Einsele, Graham Jackson, Charlotte Pawlyn, María‐Victoria Mateos, Sonja Zweegman, Martin Schreder, Meral Beksaç, Christoph Driessen, Enrique M. Ocio, Rakesh Popat, Leo Rasche, Cyrille Touzeau, Pellegrino Musto, Annemiek Broijl, Meletios Dimopoulos, Roman Hajek, Mario Boccadoro, Pieter Sonneveld   +25 more
wiley   +1 more source

Sustained disease remission after a limited duration of bispecific antibody therapy in patients with multiple myeloma. [PDF]

Hemasphere
Vega G, Morillo D, Riedhammer C, Smits F, Bag A, Julian K, Gomis NT, Gaisan CM, Bermudez MA, Shah MR, Mohyuddin GR, Dhakal B, Rasche L, Schinke C, D'Souza A, Szabo A, van de Donk NWCJ, Chakraborty R, Mohan M.   +18 more
europepmc   +1 more source

Real‐World Usage and Outcomes of Different Siltuximab Dosing Frequency in Idiopathic Multicentric Castleman Disease

American Journal of Hematology, EarlyView.
Yoshito Nishimura, Maria Santiago Estevez, Hakeem Asad, Thomas Habermann, Angela Dispenzieri   +4 more
wiley   +1 more source

Therapeutic Outcomes in VEXAS Syndrome: A Multicenter Comparative Cohort of Allogeneic Hematopoietic Stem Cell Transplantation and Hypomethylating Agents

American Journal of Hematology, EarlyView.
ABSTRACT Hypomethylating agents (HMA) and allogeneic hematopoietic stem cell transplantation (alloHSCT) have both demonstrated remissions in VEXAS; however, comparative data is lacking. We conducted a multicenter, retrospective analysis of 66 patients diagnosed with VEXAS syndrome treated with HMA (n = 35) or alloHSCT (n = 31). Baseline characteristics
Saubia Fathima, Margaret Mei‐Kay Wong, Jesus Gonzalez‐Lugo, Susan M. Geyer, Ali Alsugair, Maria Sirenko, Kimberly J. Langer, Terra L. Lasho, Christy Finke, Jun Choi, Maher Abdul‐Hay, Gary Ho, Mark R. Litzow, Aasiya Matin, Urshila Durani, Mehrdad Hefazi, William J. Hogan, Mithun V. Shah, Aref Al‐Kali, Kebede H. Begna, Naseema Gangat, Antoine N. Saliba, Ronald S. Go, Tariq Kewan, Gabriel Bartoo, Jade Kutzke, Kristen McCullough, Kenneth J. Warrington, Megan Sullivan, Kaaren K. Reichard, Horatiu Olteanu, Hemant Murthy, Talha Badar, Yael Kusne, Jeanne Palmer, Saurabh Chhabra, Nathan Punwani, Mary Riwes, Joseph P. McGuirk, Elizabeth F. Krakow, Amelia Langston, Taxiarchis Kourelis, David Dingli, James Foran, Matthew J. Koster, Mrinal M. Patnaik, David B. Beck, Hassan B. Alkhateeb, Abhishek A. Mangaonkar   +48 more
wiley   +1 more source

A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B‐Cell Lymphoma

American Journal of Hematology, EarlyView.
ABSTRACT Mosunetuzumab plus polatuzumab vedotin has shown promising activity versus rituximab plus polatuzumab vedotin (R‐Pola) in patients with relapsed/refractory (R/R) large B‐cell lymphoma (LBCL; NCT03671018). We present results from the Phase II randomized cohort, evaluating subcutaneous mosunetuzumab plus polatuzumab vedotin (Mosun‐Pola), with ...
Julio C. Chavez, Mariana Bastos‐Oreiro, Catherine Diefenbach, Izidore S. Lossos, Nirav Shah, Sarit Assouline, Adam J. Olszewski, Seema Naik, Nilanjan Ghosh, Song Pham, Michael C. Wei, Connie Batlevi, Iris To, Wahib Ead, Sneha Makadia, Elicia Penuel, Jing Jing, Lihua E. Budde   +17 more
wiley   +1 more source